Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Elevation Oncology Announces Pricing of Initial Public Offering

June 24, 2021
NEW YORK, NY – June 24, 2021 – Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers,…

Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

June 23, 2021
Boston, MA – June 23, 2021 – Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural…

Talaris Therapeutics Announces Closing of Initial Public Offering

May 11, 2021
BOSTON and LOUISVILLE, KY - May 11, 2021 - Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of…